Shares of Sierra Oncology Inc (NASDAQ:SRRA) rose 7% during trading on Wednesday . The company traded as high as $1.56 and last traded at $1.53. Approximately 501,368 shares traded hands during trading, an increase of 70% from the average daily volume of 295,414 shares. The stock had previously closed at $1.43.
SRRA has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Wednesday, April 17th. Wedbush restated an “outperform” rating on shares of Sierra Oncology in a research note on Thursday, February 28th.
The company has a market cap of $109.04 million, a P/E ratio of -1.95 and a beta of 1.70. The company has a debt-to-equity ratio of 0.06, a quick ratio of 13.07 and a current ratio of 13.07.
Hedge funds have recently made changes to their positions in the business. Blair William & Co. IL boosted its holdings in Sierra Oncology by 73.3% during the 1st quarter. Blair William & Co. IL now owns 29,319 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 12,400 shares during the last quarter. Brookstone Capital Management purchased a new position in Sierra Oncology during the 1st quarter worth $28,000. Virtu Financial LLC purchased a new position in Sierra Oncology during the 1st quarter worth $32,000. Acadian Asset Management LLC boosted its holdings in Sierra Oncology by 5.4% during the 4th quarter. Acadian Asset Management LLC now owns 407,105 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 20,754 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Sierra Oncology by 4.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,895,334 shares of the biotechnology company’s stock worth $3,241,000 after acquiring an additional 86,550 shares during the last quarter. Institutional investors and hedge funds own 64.56% of the company’s stock.
WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://weekherald.com/2019/05/17/sierra-oncology-srra-stock-price-up-7.html.
About Sierra Oncology (NASDAQ:SRRA)
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Read More: Why are percentage decliners important?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.